Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK intends to sell its remaining stake in Haleon
12:33pm, Thursday, 16'th May 2024
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
Here's Why GSK (GSK) is a Strong Value Stock
10:46am, Wednesday, 08'th May 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
01:00am, Tuesday, 07'th May 2024
BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for seri
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon – Markets Defused
06:01am, Saturday, 04'th May 2024
Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news Apple impressed Wall Street, Cook promises AI growth Sony stepped in wi
GSK plc (GSK) Q1 2024 Earnings Call Transcript
12:00am, Saturday, 04'th May 2024
GSK plc (NYSE:GSK ) Q1 2024 Earnings Conference Call May 1, 2024 3:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Comm
Why GSK (GSK) is a Top Growth Stock for the Long-Term
10:46am, Friday, 03'rd May 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
03:01pm, Thursday, 02'nd May 2024
U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Inge
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
01:26pm, Wednesday, 01'st May 2024
Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
12:11pm, Wednesday, 01'st May 2024
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
08:05am, Wednesday, 01'st May 2024
GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago.
GSK beginning to alleviate long-held concerns, say analysts
04:31am, Wednesday, 01'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) is approaching 18-month highs after the pharma group's boss Emma Walmsley raised the full-year outlook on the back of strong first-quarter results, with analysts saying pe
GSK Q1 beats consensus and FY numbers upgraded after vaccines boost
03:12am, Wednesday, 01'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) has confirmed what recent prescription data hinted at: Its vaccines business is firing on all cylinders. Bumper sales of jabs for shingles and the cold-like condition RSV w
GSK raises full-year profit forecast
02:08am, Wednesday, 01'st May 2024
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
01:56pm, Tuesday, 30'th Apr 2024
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
01:30pm, Tuesday, 30'th Apr 2024
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting in
